UPERIO PILLS 50MG

Composition

Active ingredient: sacubitrile and valsartan hydrate complex of sodium salts - 56.551 mg (in terms of anhydrous acid form 50 mg, equivalent to 24.3 mg of sacubitrile and 25.7 mg of valsartan)

Release form

Tablets for ingestion of 28 pieces per pack

pharmachologic effect

The action of the drug Yuperio is mediated by a new mechanism, namely: the simultaneous suppression of the activity of neprilysin (neutral endopeptidase (neutral endopeptidase, NEP)) with LBQ657 (the active metabolite of sacubitrile) and blockade of receptors for angiotensin II of the 1st type (AT1) valsartan and that is a virus that is an antiviral receptor that is an antiviral receptor blockade of type 1 angiotensin II (AT1) valsartan, which is an antifungal receptor blockade. II (APA II). The mutually complementary beneficial effects of sacubitril and valsartan on the cardiovascular system and kidney condition in patients with heart failure are due to an increase in the number of peptides cleaved by neprilisin (such as natriuretic peptides (NP)), which is mediated by LBQ657, and the negative effects of angiorensin II are suppressed by valsartan.

Indications for use

Chronic heart failure (NYHA Class II-IV) in patients with systolic dysfunction to reduce the risk of cardiovascular mortality and hospitalization for heart failure.

Dosage and administration

The time of taking the drug Juperio does not depend on the time of eating.

The target (maximum daily) dose of Yuperio is 200 mg (102.8 mg + 97.2 mg) 2 times a day. The recommended initial dose of Yuperio is 100 mg (51.4 mg + 48.6 mg) 2 times a day.

In patients who have not previously received therapy with ACE or APA II inhibitors, or who have received these drugs in low doses, the patient should be given 50 mg (25.7 mg + 24.3 mg) 2 times a day with a slow dose increase ( doubling the daily dose 1 time in 3-4 weeks).

Depending on the tolerability, the dose of Yuperio should be doubled every 2-4 weeks until the target (maximum daily) dose of 200 mg (102.8 mg + 97.2 mg) is reached 2 times a day.

Use of the drug Yuperio is possible not earlier than 36 hours after discontinuation of the ACE inhibitor, since in case of simultaneous use, angioedema may occur.

Since ARPA II valsartan is part of the drug, it should not be used simultaneously with another drug that includes ARA II.

If patients have problems with the tolerability of the drug Yuperio (clinically pronounced decrease in blood pressure, hyperkalemia, impaired renal function), consider a temporary dose reduction or dose adjustment of concomitant medications.

Contraindications

• Hypersensitivity to sacubitril or to valsartan, as well as to other auxiliary components of the drug.
• Simultaneous use with inhibitors of an angiotensin-converting enzyme (ACE), and also the period of 36 hours after cancellation of ACE inhibitors.
• The presence of angioedema in history against the background of previous therapy with ACE or APA II inhibitors.
• Simultaneous use with aliskiren in patients with diabetes mellitus or in patients with moderate or severe renal impairment (eGFR <60 ml / min / 1.73 m2 of body surface area).
• Severe liver function impairment (Child Pugh class C), biliary cirrhosis and cholestasis.
• The drug Intresto is not recommended for use in children under the age of 18 years due to the lack of data on efficacy and safety.
• Pregnancy, pregnancy planning and breastfeeding period.
• Simultaneous use with other drugs containing ARA II, because The drug contains valsartan.

Storage conditions

At a temperature not higher than 25 ° С. Keep out of the reach of children.